Adjuvant Treatment of Tongue and Floor of the Mouth Cancers

Abstract
Chemotherapy of head and neck cancers gives objective responses in about 30% of the cases, sometimes spectacular but never durable enough to significantly after prognosis. One of its limitations seems to be related to the tumor mass. It is, therefore, important to test chemotherapy on the residual cells, which are not visible, but are responsible for local, regional, or distant relapses after apparently satisfactory local treatment. These residual cells are also the proposed target for adjuvant immunotherapy.

This publication has 0 references indexed in Scilit: